Martin is a Senior Associate in the London office. Prior to joining F-Prime in 2019, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication.

Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.

  • CHARM Therapeutics is a 3D deep-learning research Company discovering and developing transformational medicines. Based on the award-winning discoveries of David Baker in protein-folding, CHARM has developed a proprietary technology based on the first rapid, accurate protein/ligand co-folding algorithm. The Company’s mission is to use these insights to address challenging targets in cancer and other disease areas and discover and develop new drugs against these targets. Learn more at www.charmtx.com.


  • RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The RIGImmune development candidates act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The lead development candidate at RIGImmune is RIG-101.

    The company was co-founded by the prominent Yale University professors, Anna Marie Pyle, Ph.D. and Akiko Iwasaki, Ph.D., who currently serve as scientific advisors to the company. Dr. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on the cytosolic protein, RIG-I. Dr. Pyle is also a specialist in RNA structure and design. She designed the stem-loop RNA therapeutics (SLR) for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds in collaboration with Dr. Iwasaki, whose expertise in mucosal immunity has been highly sought during the COVID-19 pandemic.

    RIGImmune is a UConn Technology Incubation Program (TIP) company located in Farmington, CT, was founded by Yale scientists, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists. Learn more at rigimmune.com.